In this episode of AMCP Unscripted Podcast, Steve Kheloussi, Principal Consultant with Kheloussi Consulting, speaks with Dr. Kirollos Hanna, Director of Pharmacy at Minnesota Oncology and Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine, about precision oncology in advanced breast cancer and the role of managed care. They discuss the evolving use of biomarker testing and circulating tumor DNA to identify ESR1 mutations, considerations for coverage and prior authorization, and the need to better align laboratory, medical, and pharmacy benefits as new evidence and treatment approaches emerge. This podcast is sponsored by AstraZeneca.

Update on the AMCP Research Institute Project: Advancing Coverage for Comprehensive Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC): A LUNGevity and American Cancer Society Cancer Action Network (ACS CAN) Research Initiative.

In this episode of Unscripted, Steve Kheloussi, Principal Consultant with Kheloussi Consulting, speaks with Rachel Ungar, Director of Research and Data Analytics at the Economic Alliance for Michigan, about bringing employers, health plans, providers, and patient advocates together to improve access to evidence-based precision oncology care. They discuss biomarker testing, payer coverage policies, the importance of aligning testing and treatment decisions, and practical steps health plans can take to reduce barriers while supporting high-quality, cost-effective cancer care.

Learn more about AMCP Research Institute. Our vision is to become the trusted source of evidence, innovation, and insights shaping the future of managed care pharmacy — through strategic partnerships, advanced data capabilities, and collaborative research.

In this episode of the AMCP Unscripted podcast, host Steve Kheloussi, PharmD, principal consultant with Kheloussi Consulting and a managed care pharmacist, is joined by Tianyi Wang, consultant at Omnicom Health Market Access, and Irvin Molina, PharmD, BCOP, director of clinical pharmacy at IPD Analytics and a board-certified oncology pharmacist, to explore how National Comprehensive Cancer Network (NCCN) guidelines influence payer policy and patient access in non-small cell lung cancer (NSCLC).

AMCP's Q3 2026 Precision Medicine Bulletin is now available, featuring a recap of key precision medicine developments from 2026, a review of recent clinical guidelines, highlights from new publications in the field, and updates on AMCP's submission to the National Comprehensive Cancer Network (NCCN).

In this episode of the AMCP Unscripted podcast, platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. In this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE® (mirvetuximab soravtansine-gynx), examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc.

In this episode of Unscripted, guest host Steve Kheloussi, Principal Consultant with Kheloussi Consulting, sits down with Dr. John Fox, Senior Medical Director for the Americas at Illumina, to untangle the complexities of clinical utility. Drawing on his experience as a pediatrician and former health plan medical director, Dr. Fox explains why defining clinical utility remains a challenge for the industry and explores its critical role in precision medicine. From ending the "diagnostic odyssey" in pediatric rare diseases to the life-saving impact of large-panel biomarker testing in oncology, they discuss how the true value of a test lies in its power to change patient management and improve net health outcomes.

At the start of each year, AMCP brings together its Board, Foundation Officers, Committee & Affiliate leaders, and corporate partners for the Winter Leadership Meeting. It’s where we align on priorities, strengthen relationships, and ensure the work ahead reflects AMCP’s mission and trends and topics in managed care pharmacy.

Researchers from University of Utah Report Findings in Managed Care and Specialty Pharmacy (Optimization of Oncology Biomarker Testing In Managed Care: Best Practices and Consensus Recommendations From an Amcp Market Insights Program): Drugs and Therapies – Managed Care and Specialty Pharmacy

In this episode of Unscripted, the AMCP podcast, we talk with Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, about the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy, key NCCN guideline considerations across lines of treatment, and the clinical and economic impact of timely access to HER2-directed therapies. We also discuss payer-provider collaboration strategies to improve testing, coverage alignment, and patient access in this rare and aggressive form of cancer.

Personalized medicine has moved from concept to proven science—but implementation lags behind. In this episode of Unscripted, Daryl Pritchard, Senior Vice President of Science Policy at the Personalized Medicine Coalition, discusses how precision medicine is transforming care and where critical gaps remain. He shares findings from recent studies showing how many patients are still lost along the testing-to-treatment pathway, even in well-established areas like non-small cell lung cancer, and explains what’s needed to bridge those gaps. The conversation highlights the role of payers, providers, and policymakers in aligning science, practice, and policy to deliver truly individualized care.